| Autor: |
Crowther MA; Division of Hematology and Thromboembolism, McMaster University Faculty of Health Sciences, St Joseph's Hospital, 50 Charlton Ave. East, Hamilton, Ontario, Canada. crowthrm@mcmaster.ca, Garcia D, Ageno W, Wang L, Witt DM, Clark NP, Blostein MD, Kahn SR, Schulman S, Kovacs M, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C |
| Jazyk: |
angličtina |
| Zdroj: |
Thrombosis and haemostasis [Thromb Haemost] 2010 Jul; Vol. 104 (1), pp. 118-21. Date of Electronic Publication: 2010 May 10. |
| DOI: |
10.1160/TH09-12-0822 |
| Abstrakt: |
Unanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarin-treated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
